Risk adjusted net present value: What is the current valuation of Daiichi Sankyo’s Raludotatug Deruxtecan?

Raludotatug Deruxtecan is a monoclonal antibody conjugated commercialized by , with a leading Phase I program in Renal Cell Carcinoma. According to Globaldata, it is involved in 1 clinical trial, whic

Website link :https://adquash.com/news_q.php?str=Risk_adjusted_net_present_value:_What_is_the_current_valuation_of_Daiichi_Sankyo’s_Raludotatug_Deruxtecan_107